drugset
drugset / Trial / NCT05130450

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

NCT05130450 ↗

Phase 3 Active not recruiting 60 enrolled Ionis Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.

Timeline

Start
2021-11-18
Primary completion
2028-02
Completion
2028-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Olezarsen Antisense oligonucleotide — Subcutaneous

Indications

familial chylomicronemia syndrome